Amgen's Bold $200M Move into India and Global Health Updates

Amgen invests $200M in India's tech center to leverage AI for drug development. The U.S. FDA seeks to rehire 300 staff including those for Neuralink. Saudi Arabia reaffirms $500M towards polio eradication. U.S. illegal vape sales hit $2.4B in 2024 per Circana data.

Amgen has announced a significant investment of $200 million in its new technology center in southern India, as confirmed by CEO Robert Bradway. The move aims to advance AI and data science in drug development.

In other news, the U.S. FDA attempts to reinstate around 300 recently dismissed scientists, including some who review Neuralink, under scrutiny following a personnel shake-up in the Trump administration.

Additionally, Saudi Arabia recommits with a $500 million pledge to the Global Polio Eradication Initiative. Meanwhile, unauthorized vape sales in the U.S. reached $2.4 billion in 2024, maintaining a substantial presence despite regulatory challenges.